Clinical trial · Observational
Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma
NCT04892810CI-TRIAL-00119000PAI²HCCcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This cohort study compares immune response induced in two groups of small HCC patients treated by ablation (group1 RFA, group 2 MWA). Patients will benefit for tumoral and non tumoral biopsies prior to treatment and stepped peripheral blood samples juste before ablation and during the first month after.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- RFA
- description
- Patient with HCC and decision of treatment with ablation
- interventionNames
- Procedure: Percutaneous ablation
- label
- MWA
- description
- Patient with HCC and decision of treatment with ablation
- interventionNames
- Procedure: Percutaneous ablation
Primary outcomes (1)
- measure
- To compare induced immunomodulation by RFA and MWA in HCC patients
- timeFrame
- one month
- description
- Comparison of modulation of immune cells (frequency, activity, function) between the two groups. Study of immune cells will include T cells with immune checkpoints molecules (PD-1+ CD8+ T, 4-1BB+ CD8+ T, LAG-3+ CD8+ T, Tim-3+ CD8+ T, COS+ CD8+ T) before and after the treatment (day 0, day 2, day 7, day 30)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven HCC for less than 3 months before ablation * Decision of ablation treatment in multidisciplinary meeting Exclusion Criteria: * Fibrolamellar HCC * Hepatocholangiocarcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.